Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

BIS in Critically Ill Patients in ICU

6 de mayo de 2026 actualizado por: Mahidol University

The Comparison of Bispectral Index Parameter Between Critically Ill Patients With and Without Decreased Mental Status and Its Association With Clinical Outcomes

The Bispectral Index (BIS) is a monitor that converts brain electrical activity from EEG into a simple number from 0 to 100. A higher number means the patient is more awake, while a lower number means deeper sedation or reduced brain activity.

In general, 100 means fully awake, 80 suggests light to moderate sedation, 60 is commonly used as a target for general anesthesia with a low chance of awareness, 40 indicates deep anesthesia, 20 suggests marked brain suppression with burst suppression on EEG, and 0 indicates no detectable cortical electrical activity.

Although BIS was originally developed for use in the operating room, it has also been applied in the ICU to help guide sedation, avoid over- or under-sedation, and assess consciousness in patients who cannot be evaluated reliably using standard clinical scores. BIS has also been studied as a possible tool for predicting outcomes in comatose ICU patients, such as those after cardiac arrest, stroke, encephalitis, or traumatic brain injury. However, evidence is still limited for its use in predicting outcomes among ICU patients with any form of decreased consciousness. Therefore, this study was conducted to explore that role.

Descripción general del estudio

Estado

Aún no reclutando

Intervención / Tratamiento

Descripción detallada

The Bispectral Index is the output of a multi-stage process that transforms the brain's electrical activity into a simplified metric. This process begins with non-invasive data acquisition and proceeds through advanced computational analysis to derive the final index.

The BIS monitor translates the EEG data into a number on a scale from 0 to 100. This index is designed to provide a direct measure of a patient's level of consciousness and response to sedation, with specific numeric ranges corresponding to general clinical states.

The generally accepted clinical correlations for the BIS scale are as follows:

  • 100: This value indicates a patient who is fully awake and alert, corresponding to a state of responsiveness to a normal voice.
  • 80: This range is typically associated with light to moderate sedation or anxiolysis. A patient in this range may respond to loud verbal commands or mild physical stimulation, such as prodding or shaking.
  • 60: This value is a critical threshold often targeted for general anesthesia. It represents a low probability of explicit recall and unresponsiveness to verbal stimuli. A BIS value of less than 60 has a high sensitivity for identifying a state of drug-induced unconsciousness, making it a key target in the operating room to prevent awareness.
  • 40: This range signifies a deep hypnotic state, with a greater degree of cortical suppression than is typically required for general anesthesia.
  • 20: A BIS value in this range indicates the presence of burst suppression on the EEG. This pattern, characterized by periods of electrical activity (bursts) alternating with periods of isoelectricity (suppression), reflects a very deep level of brain suppression seen with high doses of anesthetic agents or in conditions like barbiturate coma or severe anoxic brain injury.
  • 0: A BIS value of 0 represents a flatline or isoelectric EEG, indicating the absence of detectable cortical electrical activity.

BIS monitoring was adapted from the operating room to the ICU to help manage the difficult task of sedating critically ill patients.

Its main goals in the ICU are to:

  • Prevent the risks of over- or under-sedation.
  • Provide an objective number to guide medication dosage.
  • Assess consciousness in patients who can't be evaluated by normal methods. BIS monitoring is being used more frequently to assess the depth of sedation in ICU patients, as opposed to relying solely on clinical scoring systems.

The Bispectral Index (BIS) has been used to predict clinical outcomes in ICU patients with coma from various causes, including post-cardiac arrest, cerebrovascular disease, viral encephalitis, and traumatic brain injury. However, there is limited research on using BIS to predict outcomes for patients with any decreased level of consciousness in the ICU. Therefore, this study was initiated.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Annop Piriyapatsom, M.D.
  • Número de teléfono: +66 2419 7990
  • Correo electrónico: annop.pir@mahidol.ac.th

Ubicaciones de estudio

    • Bangkok
      • Bangkok Noi, Bangkok, Tailandia, 10700
        • Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University
        • Contacto:
        • Investigador principal:
          • Annop Piriyapatsom, M.D.
        • Sub-Investigador:
          • Chatchawan Uacharuporn, M.D.
        • Sub-Investigador:
          • Tanuwong Viarasilpa, M.D.
        • Sub-Investigador:
          • Nattachai Hemtanon, M.D.
        • Sub-Investigador:
          • Suchanun Lao-amornphunkul, M.D.
        • Sub-Investigador:
          • Natthicha Papbamnarn, M.D.
        • Sub-Investigador:
          • Chayanan Thanakiattiwibun

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Age≥18years
  2. RASS score ≤ -3 as case
  3. RASS score 0 to -1 as control
  4. Expected ICU length of stays ≥ 24hours

Exclusion Criteria:

  1. Contraindication for BIS monitoring (wound or infection at forehead)
  2. No space for attach BIS monitoring at forehead
  3. Patient with sedative drugs (Propofol, Midazolam, Dexmedetomidine)
  4. Patient with acute stroke
  5. Patient was already on EEG monitoring
  6. Denied by patients or patient's surrogates

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Decreased mental status
Monitor processed EEG using BIS
Comparador de placebos: Normal mental status
Monitor processed EEG using BIS

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
BIS value
Periodo de tiempo: 24 hours following inclusion
Average BIS value during 24 hours period of monitoring
24 hours following inclusion

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Length of stay in SICU
Periodo de tiempo: Up to 90 days following inclusion
Total days of stay in SICU
Up to 90 days following inclusion
Length of stay in hospital
Periodo de tiempo: Up to 90 days following inclusion
Total days of stay in hospital
Up to 90 days following inclusion
SICU discharge status
Periodo de tiempo: Up to 90 days following inclusion
Status whether alive or decease
Up to 90 days following inclusion
Hospital discharge status
Periodo de tiempo: Up to 90 days following inclusion
Status whether alive or decease
Up to 90 days following inclusion
Status at 30 days
Periodo de tiempo: Up to 30 days following inclusion
Status whether alive or decease
Up to 30 days following inclusion
Status at 90 days
Periodo de tiempo: Up to 90 days following inclusion
Status whether alive or decease
Up to 90 days following inclusion
ICU Memory
Periodo de tiempo: Up to 90 days following inclusion

ICU Memory Tool:

Three domains: ICU environment (family, alarms, tubes), feelings (pain, agitation, confusion), delusions (dreams, hallucinations).

A self-rated format for frequency, ranging from 0 to 2 (never, sometimes, and often).

Up to 90 days following inclusion
Post-traumatic Stress Disorder
Periodo de tiempo: Up to 90 days following inclusion
Post-traumatic Stress Disorder (PTSD) assessed by Impact of Event scale (IES)-6 which comprised 6 questions, each scored from 0 to 4 (Not at all, a little bit, moderately, quite a bit, extremely). Mean IES-6 score ≥ 1.75 considers positive screening for PTSD.
Up to 90 days following inclusion

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de mayo de 2026

Finalización primaria (Estimado)

31 de enero de 2027

Finalización del estudio (Estimado)

31 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

3 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

6 de mayo de 2026

Publicado por primera vez (Actual)

13 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 037/2569(IRB1)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Marco de tiempo para compartir IPD

IPD and supporting information will be available once the study has already published and last for 1 year.

Criterios de acceso compartido de IPD

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir